Organic Active Ingredients TRIZ Cases

Specific dibenzothiophene-S-oxide derivatives overcome poor cell penetration by releasing atomic oxygen via UV-A light to trigger apoptosis in cancer cells.

Bryostatin-1 reduces neuroinflammatory responses while promoting remyelination, addressing progressive multiple sclerosis stages.

Amorphous AMG 706 solid-state form overcomes low solubility to deliver faster therapeutic onset.

A mutant IDH inhibitor combined with venetoclax reduces 2-HG levels and induces apoptosis, overcoming resistance mutations in acute myeloid leukemia.

Modular aryl-bipyridine amines inhibit PI5P4K to treat cancers and metabolic disorders with improved selectivity.

Asymmetric CuPTSM copper complex overcomes delivery inefficiency and manufacturing difficulties of prior agents by optimizing ligand affinity.

5-Benzylaminosalicylic acid derivatives address central nervous system side effects while maintaining antidepressant efficacy.

Ergothioneine regulates insulin signaling and autophagy pathways to extend mammalian lifespan.

Combining glucocorticoids with immunostimulating antibodies to reduce non-specific cytokine release.

Specific heterocyclic compounds inhibit ERK1/2 to overcome acquired resistance in cancer treatment.

Amide compounds inhibit the IRAK4 kinase, reducing inflammatory cytokine expression to treat diseases.

Macrocyclic compounds featuring quinolinyloxy proline moieties inhibit hepatitis C virus replication while improving pharmacokinetics and reducing cytotoxicity.

Screen chaperonin modulators using VRK2-COP1 interaction markers to prevent protein aggregation without triggering autophagy-related cell death.

Fused indole compounds bind allosterically to the oxytocin receptor, avoiding non-specific vasopressin activation and improving stability.

Modified AXL peptides target metastatic cancer cells by binding to GAS6 ligand, blocking tumor invasion pathways.

Sterically bulky estradiol analogues disrupt estrogen receptor signaling to inhibit tumor growth while avoiding agonist side effects.

CD5L:p40 heterodimers inhibit IL-23 receptor binding to suppress pathogenic T cell activity while preserving regulatory T cell function for controlled immunity.

Synthetic polymer nanoparticles target VEGF to bypass antibody discovery delays and reduce production costs.

Formulated oltipraz compositions utilize controlled particle size reduction to enhance solubility and stability in aqueous suspensions.

Spiroheptanyl hydantoin compounds selectively inhibit Rho kinase to overcome drug resistance in cardiovascular treatments.

Inhibiting CRMP2 sumoylation reduces Nav1.7 surface expression, alleviating neuropathic pain without opioid side effects.

Glycerol, dextran, and chondroitin sulfate formulation provides lubrication and deturgescence to ocular tissues.

Nasal spray formulation delivers epinephrine via mucosal absorption to achieve rapid systemic circulation.

Purified Francisella liposomes modulate immune responses to reduce inflammation while preserving adaptive immunity.

A metformin hydrochloride osmotic pump tablet uses a controlled-release coating film to reduce the cross-sectional area of the dosage form.

A keratin-based plasma expander composition solubilizes in an electrolyte solution to form a homogeneous liquid for intravenous administration.

Structural modifications in cytidine derivative dimers reduce toxicity while maintaining anti-tumor activity against colon cancer cells.

MicroRNA antagonists target miR-99a, miR-100-5p, Let-7a-5p, and Let-7c-5p to reverse ischemic injury and treat muscular dystrophy.

A pharmaceutical agent modulates mu, kappa, and ORL1 receptors with partial agonist and antagonist activities.

Novel triazolo[4,3-a]pyridine derivatives act as positive allosteric modulators of the metabotropic glutamate receptor subtype 2.

Low methoxyl pectin complexes with amino acids to mask bitterness, enabling high drug loading in palatable gummy dosage forms.

Quinazolinedione derivatives inhibit phosphodiesterase 7 and 8, increasing cAMP and cGMP concentrations to treat asthma and leukemia.

A seven-step chemical process synthesizes triazoloquinazolinones using Negishi coupling and zinc reagents.

2,3-dihydroquinazolinone compounds block retrograde transport pathways to prevent intracellular toxin action.

Selective modulation of TARP gamma 8 associated AMPA receptors by fused bicyclic pyridine compounds reduces ataxia and sedation while treating epilepsy.

HSD17B13 variants identify subjects with decreased chronic liver disease risk, addressing the lack of evidence-based therapeutic strategies.

Combining glucocorticoid receptor antagonists with androgen inhibitors overcomes resistance mechanisms to improve survival outcomes.

Small molecule compounds correct SMN2 alternative splicing to boost functional Smn protein, addressing the root cause of spinal muscular atrophy.

Tetracyclic compounds disrupt the HCV replication complex by modifying structural parameters, preventing disease progression.

Isolated matrix-bound nanovesicles deliver miRNA cargo to regulatory T cells for selective immune modulation.

Modifying naringenin at positions 6 and 8 yields stable derivatives that provide effective cough relief without codeine addiction risks.

Novel tetracyclic pyridones reduce subviral particle abundance to prevent cccDNA persistence and drug resistance.

Asymmetric synthesis and preliminary crystallization resolve the contradiction between enantiomeric purity and manufacturing scalability.

Bioadhesive and rheology-changeable polymers anchor granisetron to nasal mucosa, overcoming rapid clearance to sustain plasma concentrations.

Segmented quinazoline structures optimize therapeutic efficacy and pharmacokinetics by targeting ErbB family kinases.

A weight management system using formulations to accelerate fat metabolism while preserving lean muscle tissue.

Topical tamoxifen citrate reduces plasma metabolites to minimize uterine cancer risk while treating atrophic vaginitis.

Dextrin and saccharide excipients protect lipid nanoparticles during freeze drying, enabling stable long-term storage without degradation.

Inhibitors block BfrB-Bfd binding to starve bacteria of iron, restoring fluoroquinolone efficacy against resistant pathogens.

A buccal composition delivers D-galactose and coenzyme Q10 through the oral mucosa for rapid systemic absorption.

Topical pharmaceutical application to the face bypasses the eye to utilize neural pathways for rapid cranial nerve innervation.

Segmented twice-daily stenoparib dosing overcomes short half-life limitations to maintain therapeutic efficacy in solid tumors.

Inhibiting μ-crystallin restores normal muscle function and strength while improving metabolic parameters in sarcopenia treatment.

Modified indole acetic acid compounds resist muscle weakness and respiratory failure in amyotrophic lateral sclerosis.

Replacing expensive DIBAL reagents with inexpensive bis-electrophilic starting materials eliminates regioisomeric mixtures while maintaining product purity.

Logic gate nanocarriers use pH and ROS triggers to degrade polymers, resolving slow degradation and inflammatory side effects.

Formula (I) compounds overcome blood-brain barrier limits for KRAS G12C mutant cancer by balancing inhibition potency and metabolic stability.

Segmented antibody-drug conjugates use labile linkers to deliver pyrrolobenzodiazepines, resolving toxicity and specificity trade-offs.

Anhydrous excipient selection prevents hydrolysis of the active ingredient while maintaining ease of manufacture and enabling room temperature storage.

5-Pyridazinyl-1-azabicyclo[3.2.1]octane derivatives bind selectively to nicotinic receptors.

Phospholipid liposomes encapsulate omega-3 fatty acid salts, replacing synthetic surfactants to improve bioavailability and stability.

A biomarker profile measures signaling kinases in neuronally derived exosomes from blood samples.

High-purity lambda-carrageenan in a polyol matrix inhibits HPV while maintaining lubricity and resisting rapid drying.

Water-soluble zinc salts rapidly inhibit gastric acid secretion, raising stomach pH and resolving slow onset issues in proton pump inhibitor therapies.

A compounded topical cream uses dimethyl sulfoxide to drive active ingredients through the skin barrier.

A nasal formula containing antioxidants and essential oils targets anxiety in non-human mammals.

TβRII antagonists reduce fibrosis and splenomegaly in myelofibrosis models, addressing complications that JAK inhibitors alone cannot resolve.

Chimeric nanoparticles merge viral cores with polymeric shells to resolve gene delivery efficiency versus immune response trade-offs.

Sulfated hyaluronic acid derivatives inhibit viral entry by blocking spike protein adhesion, reducing infectious capacity by 90%.

HDL nanoparticles bind lipopolysaccharides to neutralize the inflammatory cascade and reduce sepsis mortality.

Merging obeticholic acid with bezafibrate reduces liver enzymes while minimizing pruritus associated with monotherapy.

Co-administers benzodiazepines and neurosteroids to mitigate TETS-induced seizures while reducing toxicity from high-dose monotherapy.

Segregating magnesium stearate into a dedicated aid prevents sticking while preserving hardness.

P2Y14 receptor antagonists block UDP-glucose signaling to alleviate mechano-allodynia without opioid tolerance or abuse risks.

Local quality and parameter changes in saRNA design boost TMEM173 expression while minimizing off-target effects.

Bridged tetrahydroisoquinolines target the p47phox binding interface to resolve specificity challenges among homologous Nox isoforms.

Hydroxypropyl-beta-cyclodextrin forms inclusion complexes with YC-6, resolving water insolubility and solvent irritation in neuronprotective injections.

Structural modifications of FGFR4 inhibitors balance therapeutic efficacy and safety profiles to treat cancers mediated by FGF19.

A QSP platform derives gene expression signatures from RNA-seq data to identify and prioritize drugs that reverse disease states.

Selective PI3Kδ inhibition reduces harmful side effects while maintaining treatment efficacy for inflammatory disorders.

Indole and azaindole piperazine diamide derivatives inhibit HIV infection through unique antiviral properties.

Targeting the MAPKAPK5-MMP1 axis reduces extracellular matrix degradation and joint damage while minimizing systemic side effects common with biological DMARDs.

Pyrimidine pyrazolyl compounds selectively inhibit IRAK-4 kinase activity to treat autoimmune disorders.

Intravenous cangrelor delivers rapid platelet inhibition during percutaneous coronary intervention procedures.

Chemically modified DUX4 RNAi agents target mRNA to halt muscle degeneration in facioscapulohumeral muscular dystrophy.

Segmented chitosan implants release antibiotics at wound sites, reducing systemic toxicity and infection risk.

Segmenting muscarinic acetylcholine receptor subtypes enables selective antagonism of the M4 subtype.

Replaces flammable propellants with pressurized carbon dioxide to solvate and remove sebacic acid from the scalp.

3-methylmethcathinone improves therapeutic efficacy by reducing distress in severe mental health cases.

AL-1 derivative scavenges free radicals and activates PPAR-gamma, resolving adverse effects from long medication cycles in ulcerative colitis.

C5-spiro iminothiadiazine dioxide compounds inhibit BACE enzymes through a spirocyclic molecular architecture.

Replacing gelling agents with non-gelling carrageenan eliminates physiological dissolution variability while maintaining extended quetiapine release.

Adeno-associated virus vectors deliver the frataxin gene to reverse cardiomyopathy caused by energy failure and fibrosis.